Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation

Although rituximab, a chimeric monoclonal antibody that specifically binds to CD20, has significantly improved the prognosis for diffuse large B cell lymphoma (DLBCL), one‐third of DLBCL patients demonstrate resistance to rituximab or relapse after rituximab treatment. Thus, a novel approach to ritu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Kazumi, Nagasaki, Eijiro, Kan, Shin, Ito, Masaki, Kamata, Yuko, Homma, Sadamu, Aiba, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970836/
https://www.ncbi.nlm.nih.gov/pubmed/26920337
http://dx.doi.org/10.1111/cas.12918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970836/
https://www.ncbi.nlm.nih.gov/pubmed/26920337
http://dx.doi.org/10.1111/cas.12918

Ejemplares similares